Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) EBT (2016 - 2025)

Historic EBT for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $52.6 million.

  • CorMedix's EBT rose 199340.07% to $52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.0 million, marking a year-over-year increase of 35164.6%. This contributed to the annual value of -$19.3 million for FY2024, which is 5829.71% up from last year.
  • Latest data reveals that CorMedix reported EBT of $52.6 million as of Q3 2025, which was up 199340.07% from $20.3 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's EBT registered a high of $52.6 million during Q3 2025, and its lowest value of -$15.9 million during Q1 2024.
  • In the last 5 years, CorMedix's EBT had a median value of -$7.5 million in 2021 and averaged -$948502.3.
  • In the last 5 years, CorMedix's EBT tumbled by 5044.48% in 2023 and then skyrocketed by 199340.07% in 2025.
  • Quarter analysis of 5 years shows CorMedix's EBT stood at -$7.8 million in 2021, then fell by 5.36% to -$8.2 million in 2022, then dropped by 18.7% to -$9.7 million in 2023, then skyrocketed by 238.18% to $13.5 million in 2024, then soared by 290.48% to $52.6 million in 2025.
  • Its EBT was $52.6 million in Q3 2025, compared to $20.3 million in Q2 2025 and $20.6 million in Q1 2025.